Objective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short-and longer-term effi cacy, the moderating effect of comorbid disorders, as well as short-and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-defi cit/hyperactivity disorder (ADHD). Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric

more »

... and/or adolescent ADHD. Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short-and longer-term effi cacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine's therapeutic potential for other psychiatric conditions. Short-and longerterm safety and tolerability continue to be reported. Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine's evidence base, including its profi le of clinical response and its possible effectiveness in the presence of comorbidity.